Business
Hoth Announces Pricing of Public Offering of Shares of Common Stock
NEW YORK, May 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, today announced the
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, May 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (\"Hoth\" or the \"Company\") (NASDAQ: HOTH), a biopharmaceutical company, today announced the pricing of an underwritten public offering of 1,818,182 shares of common stock at a public offering price of $2.75 per share, before underwriting discounts and commissions. In addition, Hoth has granted the underwriters a 45-day option to purchase up to an additional 272,727 shares of common stock at the public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by Hoth. Gross proceeds from the offering will be approximately $5.0 million. The offering is expected to close on or about May 27, 2020, subject to the satisfaction of customary closing conditions. \n\n \n \n \n \n \n \n\n \nThe Benchmark Company is acting as sole book-running manager for the offering.\nA registration statement on Form S-3 (including a preliminary prospectus describing the terms of the offering) relating to these securities has been filed with the Securities and Exchange Commission (SEC) and has become effective. The offering will be made only by means of a prospectus supplement and accompanying prospectus. A copy of the final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and may be obtained, when available, for free on the SEC's website located at http://www.sec.gov. When available, electronic copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained by contacting The Benchmark Company, Attn: Prospectus Department, 150 E. 58th Street, 17th floor, New York, NY 10155 or by calling 212-312-6700 or by emailing [email protected].\nThis press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nAbout Hoth Therapeutics, Inc.\nHoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suf...